Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro

INTRODUCTION: Upregulation of PI3K/Akt/mTOR signalling in endocrine-resistant breast cancer (BC) has identified mTOR as an attractive target alongside anti-hormones to control resistance. RAD001 (everolimus/Afinitor®), an allosteric mTOR inhibitor, is proving valuable in this setting; however, some...

Descripción completa

Detalles Bibliográficos
Autores principales: Jordan, Nicola J, Dutkowski, Carol M, Barrow, Denise, Mottram, Huw J, Hutcheson, Iain R, Nicholson, Robert I, Guichard, Sylvie M, Gee, Julia MW
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978713/
https://www.ncbi.nlm.nih.gov/pubmed/24457069
http://dx.doi.org/10.1186/bcr3604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978713/
https://www.ncbi.nlm.nih.gov/pubmed/24457069
http://dx.doi.org/10.1186/bcr3604

Ejemplares similares